Who Paid My Doc
Osocimab in ESRD Phase 2b study
Research payments
$3,133,547
Through program year 2021, $3,133,547 in research payments was reported against Osocimab in ESRD Phase 2b study, across 435 payments, paid by Bayer HealthCare Pharmaceuticals Inc..
- Paid by
- Bayer HealthCare Pharmaceuticals Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $2,980,086 | 416 |
| 2020 | Research | $153,461 | 19 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Ahmed Awad Kansas City, MO Named on 39 payments
- Marializa Bernardo Houston, TX Named on 21 payments
- Andrew Patchett St George, UT Named on 21 payments
- Arnold Silva Meridian, ID Named on 20 payments
- George Fadda La Mesa, CA Named on 20 payments
- Olayiwola Ayodeji Hampton, VA Named on 19 payments
- Amarnath Kathresal Durham, NC Named on 19 payments
- Jill Meyer Chula Vista, CA Named on 18 payments
- Kenneth Kleinman Tarzana, CA Named on 18 payments
- Marwan Kaskas Shreveport, LA Named on 17 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.